IRL-1620, an Endothelin-B Receptor Agonist, Enhanced Radiation Induced Reduction in Tumor Volume in Dalton’s Lymphoma Ascites Tumor Model
| Autor: | Anil Gulati, G Kuttan, E S Sunila |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Male
medicine.hormone Agonist medicine.medical_specialty Lymphoma medicine.drug_class medicine.medical_treatment Phases of clinical research Endothelins Mice Internal medicine Drug Discovery Ascites medicine Animals Receptor Chemistry Cancer medicine.disease Receptor Endothelin B Peptide Fragments Tumor Burden Radiation therapy Disease Models Animal Endocrinology medicine.symptom |
| Zdroj: | Arzneimittelforschung. 62:14-17 |
| ISSN: | 1616-7066 0004-4172 |
| DOI: | 10.1055/s-0031-1295430 |
| Popis: | ET B receptor agonist, IRL-1620 (or SPI-1620) presently in US Phase 1 clinical trial, has been demonstrated to selectively and transiently increase tumor blood flow. The present study was conducted to determine the effect of IRL-1620 on radiation therapy in tumor bearing mice inoculated with Dalton’s Lymphoma Ascites cells. Tumors were allowed to grow for 30 days to a size of 1.10–1.29 cm 3 before starting the treatment. The animals with or without IRL-1620 treatment were exposed to radiation (4 Gy/dose) on every alternate day for a total of 5 doses. Tumor volume was determined twice every week till the end of study. Radiation alone did not affect the tumor volume; however, animals treated with IRL-1620 followed by radiation produced a significant (64%) reduction in tumor volume. Survival of mice improved from 0/10 at 56 days after tumor inoculation in vehicle plus radiation group to 6/10 at 70 days in IRL-1620 (9 nmol/kg) plus radiation group. It is concluded that IRL-1620 improves the efficacy of radiation treatment in tumor bearing mice. (These findings have been earlier presented as an abstract 1 ). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|